CHICAGO TRUST Co NA Grows Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

CHICAGO TRUST Co NA grew its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 67.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,236 shares of the medical device company's stock after purchasing an additional 7,373 shares during the quarter. CHICAGO TRUST Co NA's holdings in DexCom were worth $1,418,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Private Advisor Group LLC grew its position in shares of DexCom by 9.1% during the 2nd quarter. Private Advisor Group LLC now owns 10,710 shares of the medical device company's stock worth $1,214,000 after buying an additional 891 shares during the period. Oppenheimer & Co. Inc. raised its holdings in shares of DexCom by 0.8% during the second quarter. Oppenheimer & Co. Inc. now owns 34,594 shares of the medical device company's stock valued at $3,922,000 after purchasing an additional 285 shares during the period. Meeder Advisory Services Inc. boosted its position in shares of DexCom by 37.5% during the 2nd quarter. Meeder Advisory Services Inc. now owns 7,281 shares of the medical device company's stock worth $826,000 after purchasing an additional 1,986 shares in the last quarter. Thoroughbred Financial Services LLC bought a new stake in DexCom in the 2nd quarter valued at about $211,000. Finally, Envestnet Asset Management Inc. raised its stake in DexCom by 0.6% during the 2nd quarter. Envestnet Asset Management Inc. now owns 599,303 shares of the medical device company's stock worth $67,949,000 after buying an additional 3,356 shares during the period. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the company's stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares of the company's stock, valued at $5,320,178.16. This represents a 5.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.30% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. JPMorgan Chase & Co. upped their target price on DexCom from $75.00 to $85.00 and gave the stock a "neutral" rating in a research report on Friday, October 25th. Wells Fargo & Company upped their price objective on shares of DexCom from $90.00 to $94.00 and gave the stock an "overweight" rating in a report on Wednesday, December 11th. Leerink Partners reduced their price objective on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Royal Bank of Canada lowered their target price on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Finally, Sanford C. Bernstein lifted their price target on DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a research note on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $98.00.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded up $2.08 during midday trading on Monday, reaching $79.84. The company had a trading volume of 5,518,567 shares, compared to its average volume of 3,341,601. The stock has a market cap of $31.19 billion, a P/E ratio of 47.81, a P/E/G ratio of 2.36 and a beta of 1.12. The company's 50 day moving average price is $76.93 and its 200 day moving average price is $78.84. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.